Search

Displaying results 1361 - 1370 of 5419 in total
  1. Drug

    Influenza B virus B/Hong Kong/259/2010 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14464
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Medical Provider Single Use EZ Flu Shot 2018-2019
  2. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [A263126] These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue. … Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue.

  3. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    [L32813] Vildagliptin is currently under investigation in the US. … [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote

  4. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568] … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.

  5. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [A259736] The use of epcoritamab may lead to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. … [A259736,A258488] The use of epcoritamab in this group of patients has high response rates, durable complete responses and manageable adverse events with few discontinuations.

  6. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

  7. Drug

    Undecylenic acid

    go.drugbank.com/drugs/DB11117
    Approved

    Undecylenic acid also possesses antifungal properties, but is never used on its own for antifungal purposes.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  8. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64095,L64118] It is given as an intramuscular injection into the corrugator and procerus muscles, is intended for occasional use, and its potency units are not interchangeable with those of other botulinum … [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries

  9. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage.

  10. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory. It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, sup...